Endocrine therapy: Is the first generation of targeted drugs the last?

Journal of Internal Medicine

Volumn 274, Issue 2, 2013, Pages 144-152

  Pritchard, K I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Endocrine therapy; Targeted drugs

Indexed keywords

ANASTROZOLE; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LAPATINIB; LETROZOLE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG TARGETING; HORMONAL THERAPY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BREAST CANCER; ENDOCRINE THERAPY; TARGETED DRUGS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84880358667     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12065     Document Type: Review

References (37)

1. Jensen EV, Jacobson HI. Fate of steroid estrogens in target tissues. In: Pincus G, Vollmer EP, eds. Biological Activities of Steroids in Relation to Cancer. New York: Academic Press, 1960; 161-78.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7.
3. Schinzinger A. Ueber carcinoma mammae. Verh Dtsch Ges Chir 1889; 18: 28-9.
4. Yan Y, Li X, Blanchard A et al. Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are Predictive for Benefit From Tamoxifen Therapy in Patients with Estrogen Receptor-alpha (ER-α? Negative Early Breast Cancer (EBC) Ann Oncol 2013; In press.
5. Fox EM, Davis RJ, Shupnik A. ERβ in breast cancer-Onlooker, passive player, or active protector? Steroids 2008; 73: 1039-51.
6. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
7. Chooniedass-Kothari S, Vincett D, Yan Y et al. The protein encoded by the functional steroid receptor RNA activator is a new modulator of ERα transcriptional activity. FEBS Lett 2010; 6: 1174-80.
8. Yan Y, Skliris GP, Penner C et al. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res 2009; 11: R67.
9. Howell A, Robertson JF, Abram P et al. Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind randomized trial. J Clin Oncol 2004; 22: 1605-13.
10. Howell A, Robertson JFR, Albano JQ et al. Fulvestrant, formerly ICI 182, 780, Is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-403.
11. Brodie MH, Santen RJ. Aromatase and its inhibitors in breast cancer treatment - overview and perspective. Breast Cancer Res Treat 1994; 30: 1-6.
12. Bergh J, Jonsson PE, Lidbrink EK et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 16: 1919-25.
13. Johnston S. Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor- First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Presented at EBCC 2012, Abstract LBA2.
14. Mehta RS, Barlow WD, Albain KS, Vandenberg TA et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-44.
15. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
16. Baum M, Brinkley DM, Dosset JA et al. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at eight years by Nolvadex Adjuvant Trial Organization. Br J Cancer 1988; 57: 608-11.
17. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28, 896 women. N Engl J Med 1988; 319: 1681-92.
18. Fisher B, Costantino JP, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-84.
19. Fisher B, Costantino JP, Redmond C et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
20. Mobbs BG, Fish EB, Pritchard KI et al. Estrogen and progesterone receptor content of primary and secondary breast cancer: influence of time and treatment. Eur J Cancer Clin Oncol 1987; 23: 819-26 HOLD.
21. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-92.
22. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-8.
23. Dowsett M, Smith I, on behalf of the IMPACT trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treat 2003; 82: (Supp 1) S6. Br Cancer Res Treat 2003; 82:2.
24. Kaufman B, Mackey J, Clemons MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-37.
25. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-46.
26. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-24.
27. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor - positive breast cancer. J Clin Oncol 2012; 27: 2630-7.
28. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer. N Engl J Med 2011; 366: 520-9.
29. Gnant M, Hortobagyi GN, Rugo H et al. Everolimus added to exemestane reduced bone markers and disease progression in bone in postmenopausal women with advanced breast cancer: updated results from the BOLERO-2 trial. Abstract LBA3. Presented at EBCC, 2012.
30. Carpenter JT, Roché H, Baselga J et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Abstract 564. J Clin Oncol 2005; 23: A564.
31. Chow L, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Abstract 6091. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
32. Gelmon K. Understanding the hits and misses of targeted therapy: the clinician's confusion. Education Session: Developing a targeted therapy: issues in the age of personalized therapy. ASCO Annual Meeting. June 2012.
33. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 2006; 12: 4790-3.
34. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-53.
35. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005; 11(2 Pt 2): 889s-99s.
36. Bourgier C, Ray-Coquard I, Provencal J et al. Exploratory subgroup analysis of the TAMRAD phase 2 GINECO trial comparing tamoxifen (TAM) plus everolimus (RAD) with TAM alone in patients with hormonereceptor-positive, HER-2 negative metastatic breast cancer (mBC) with prior exposure to aromatase inhibitors (AIs): implication for research strategies. Eur J Cancer 2011; 47(suppl 1): S331. Abstract.
37. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127. ps10.